Angiotensin-Converting Enzyme Inhibitors
                             
                            
                            
                                
                            
                            
                                
                            
                            
                            
                                
                                    
                                            
	"Angiotensin-Converting Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
    
			
			
				
				
					
						| Descriptor ID | D000806 | 
					
						| MeSH Number(s) | D27.505.519.389.745.085 | 
					
						| Concept/Terms | Angiotensin-Converting Enzyme InhibitorsAngiotensin-Converting Enzyme InhibitorsAngiotensin Converting Enzyme InhibitorsInhibitors, Kininase IIKininase II AntagonistsKininase II InhibitorsAngiotensin I-Converting Enzyme InhibitorsAngiotensin I Converting Enzyme InhibitorsAntagonists, Angiotensin-Converting EnzymeAntagonists, Angiotensin Converting EnzymeAntagonists, Kininase IIInhibitors, ACEACE InhibitorsInhibitors, Angiotensin-Converting EnzymeEnzyme Inhibitors, Angiotensin-ConvertingInhibitors, Angiotensin Converting EnzymeAngiotensin-Converting Enzyme AntagonistsAngiotensin Converting Enzyme AntagonistsEnzyme Antagonists, Angiotensin-Converting
 | 
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "Angiotensin-Converting Enzyme Inhibitors".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "Angiotensin-Converting Enzyme Inhibitors".
				
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in this website by year, and whether "Angiotensin-Converting Enzyme Inhibitors" was a major or minor topic of these publications. 
				
					 
                    To see the data from this visualization as text, 
click here. 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 2001 | 1 | 1 | 2 | 
| 2004 | 1 | 0 | 1 | 
| 2005 | 0 | 1 | 1 | 
| 2006 | 1 | 1 | 2 | 
| 2008 | 1 | 1 | 2 | 
| 2009 | 1 | 1 | 2 | 
| 2010 | 3 | 2 | 5 | 
| 2011 | 2 | 1 | 3 | 
| 2012 | 2 | 2 | 4 | 
| 2013 | 1 | 0 | 1 | 
| 2014 | 0 | 1 | 1 | 
| 2015 | 1 | 4 | 5 | 
| 2016 | 0 | 1 | 1 | 
| 2017 | 4 | 0 | 4 | 
| 2018 | 1 | 1 | 2 | 
| 2019 | 2 | 3 | 5 | 
| 2020 | 4 | 5 | 9 | 
| 2021 | 2 | 3 | 5 | 
| 2022 | 1 | 3 | 4 | 
| 2023 | 0 | 1 | 1 | 
| 2024 | 0 | 1 | 1 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in Profiles.
						
					
								- 
								National Trends in Hospital Performance in Guideline-Recommended Pharmacologic Treatment for Heart Failure at Discharge. JACC Heart Fail. 2024 Jun; 12(6):1059-1070. 
- 
								Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes. Am J Nephrol. 2023; 54(7-8):258-267. 
- 
								Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity. Am J Med. 2022 12; 135(12):1468-1477. 
- 
								Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25?000 Medicare beneficiaries. Eur J Heart Fail. 2022 Sep; 24(9):1506-1515. 
- 
								A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. Am Heart J. 2022 May; 247:76-89. 
- 
								Laboratory monitoring to reduce adverse drug-related events: a mixed methods study. J Manag Care Spec Pharm. 2022 Jan; 28(1):16-25. 
- 
								Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease. Pharmacotherapy. 2021 12; 41(12):998-1008. 
- 
								Physician adjudication of angioedema diagnosis codes in a population of patients with heart failure prescribed angiotensin-converting enzyme inhibitor therapy. Pharmacoepidemiol Drug Saf. 2021 12; 30(12):1630-1634. 
- 
								Incidence and Outcomes of Pneumonia in Patients With Heart Failure. J Am Coll Cardiol. 2021 04 27; 77(16):1961-1973. 
- 
								Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study. Am J Hypertens. 2021 04 20; 34(4):339-347.